Received Dec 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 3 | FF2587 | IM / LA |
Received Pfizer COVID vaccine booster on 19Nov2021. Within 24 hours developed high fever for 2-3 days, and large left axillary swelling that lasted for weeks. Was then exposed to COVID in Feb/March 2022 with cough and fever. Then developed severe abdominal pain, gastritis, reflux, migraines, brain fog, memory loss, hives, mast cell disorder, frequent infections, bladder motility disorder, colon motility disorder, night sweats, fatigue, pins and needles feeling in extremities, mieobian glad dysfunction, swollen lymph nodes
None
None prior to vaccination
only Jolessa (birth control)
None
? Gastrointestinal testing confirming Small Intestinal Bacterial Overgrowth (SIBO) with recurrent flares despite treatment ? Laboratory and clinical findings consistent with Mast Cell Activation Syndrome (MCAS), with inadequate response to standard MCAS therapies ? Ongoing evaluation for mast cell disease/mastocytosis, including serum tryptase testing and referral to a mast cell specialist ? Repeated blood work demonstrating chronic inflammatory patterns and nutritional deficiencies (including borderline vitamin B12) ? Endoscopy and colonoscopy to evaluate chronic abdominal pain, inflammation, and dysmotility (no alternative unifying diagnosis identified) ________________________________________ ? Multiple physician and specialist visits (gastroenterology, allergy/immunology, mast cell specialist) ? Emergency room visits for severe abdominal pain and systemic reactions, treated with corticosteroids and supportive care ? Long-term chronic illness requiring daily medications, dietary restriction, and ongoing medical management ? Significant impact on quality of life and daily functioning over a period exceeding three years ? Symptoms have not resolved and remain ongoing at the time of this report
2nd Dose COVID 19 Vaccination on 05 March 2021: Moderna LOT# 027A21A, had transient fever resolved in 24 hours